Stephen Dilly, MBBS, PhD
President, Chief Executive Officer & Board Member, Sierra Oncology
Stephen Dilly was appointed Chairman of the DNAtrix Board of Directors in July 2019. Dr. Dilly is the President, Chief Executive Officer and Board Member of Sierra Oncology. Dr. Dilly serves on several additional Boards, including as a Board Member of Codexis and Adjuvance Technologies, and as the Chairman of Cognoa. Dr. Dilly is also on the Industry Advisory Board of Longitude Ventures. From April 2013 to June 2018, he served as Chief Executive Officer and Board Member of Aimmune Therapeutics and currently serves as Special Advisor on Clinical and Regulatory affairs. Prior to that, Dr. Dilly was successively Chief Executive Officer and Board Member of PhotoThera, Inc., a medical device company with a product in Phase 3 clinical trials for the treatment of ischemic stroke, and APT Pharmaceuticals, a therapeutics company with a product in Phase 3 for lung transplant. From 2003 to 2006, he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company that was acquired by Novartis International AG. From 1998 to 2003, Dr. Dilly held positions of Vice President of Development Sciences and Vice President of Medical Affairs at Genentech. Earlier in his career, he held various management positions with SmithKline Beecham, most recently as Vice President of Clinical Neuroscience. Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. In 1982, Dr. Dilly earned his M.B.B.S., the equivalent of an M.D. in the U.S., from the University of London in the U.K. and received his Ph.D. in Cardiac Physiology from University of London in 1988.
Chief Executive Officer, dnatrix
Jeff Knapp has over 30 years of experience in the pharmaceutical industry, including 20 in executive management. He has developed and executed strategies supporting clinical development, regulatory approval, and commercial launch of multiple products across a diverse array of therapeutic areas. Prior to joining DNAtrix, Jeff served as Chief Operating Officer at Aimmune Therapeutics where he was responsible for preparing the company’s first asset, AR101, for approval and commercial launch in the US & EU as a treatment for children and adolescents with peanut allergies. Before joining Aimmune, Jeff served as Chief Operating Officer at Adamas Pharmaceuticals. While working with Adamas, Jeff established the preliminary commercial and manufacturing infrastructure as the company moved from a privately held Phase 2 company to a publicly-traded Phase 3 / pre-commercial company and supported the company’s successful Initial Public Offering in April 2014. Jeff also served as Chief Commercial Officer at Affymax, where he developed the strategy and led the build out of the commercial organization leading to the successful 2012 launch of the company’s lead compound, OMONTYS® (peginesatide), for the treatment of anemia in patients with end-stage renal disease. Earlier in his career, Jeff held several senior positions in Sales and Marketing, including Senior Vice President and Vice President, at companies such as Abgenix (acquired by Amgen in April 2006), Pharmion Corporation, EMD Pharmaceuticals (a division of Merck KGaA), and the Oncology Division of Eli Lilly and Schering-Plough Corporation. Jeff received a BA in Biology with a Minor in Business Administration from Wittenberg University.
Isaac Cheng, MD
Dr. Cheng joined Morningside in 2006 and focuses on biopharmaceutical and healthcare investments. He is currently a director of Liquidia Technologies, Cognoa, K-Gen, Artugen Therapeutics, Cognito Therapeutics, Amylyx Pharmaceuticals, NuCana PLC (NASDAQ:NCNA) and Alms Therapeutics. Previously he was a board member of Advanced Cell Diagnostics (sold to Bio-Techne). Prior to joining Morningside, Dr. Cheng was Director of Research and Development at Serica Technologies, a Morningside portfolio company which was sold to Allergan. In addition, Dr. Cheng was previously an Associate Director at Novartis Pharmaceuticals in Clinical Development and Medical Affairs. Dr. Cheng received his M.D. from Tufts University School of Medicine. He is the recipient of numerous honors and awards including the Howard Hughes Medical Institute Research Fellowship, which supported his research under Dr. Rudy Tanzi at Massachusetts General Hospital / Harvard Medical School.
Chief Financial Officer, Atreca, Inc.
Herb Cross is the Chief Financial Officer of Atreca and has more than 20 years of experience in executive leadership roles with responsibility for strategic financial management and corporate operations. He also serves on the Board of Directors, and is the Chair of the Audit Committee, of Apexigen, Inc., a privately held immuno-oncology company focused on developing antibody therapeutics for solid tumors. His operating experience includes leading the successful initial public offering of Atreca in 2019 as well as serving in other Chief Financial Officer roles at a number of life sciences companies, including ARMO BioSciences, Balance Therapeutics, KaloBios Pharmaceuticals and Affymax. Earlier in his career, he also served as Vice President of Finance at Neoforma, PDL BioPharma and Facet Biotech. While at ARMO, Mr. Cross led all administrative functions and corporate development in driving their successful 2018 initial public offering as well as the subsequent acquisition of the company by Eli Lilly for $1.6 billion. Mr. Cross received a B.S. in Business Administration from the University of California, Berkeley and is a certified public accountant.
Drew Pardoll, MD, PhD
Professor, Johns Hopkins University of Medicine
Drew Pardoll is Seraph Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University of Medicine. He is Co-Director of the Cancer Immunology Program in the Sydney Kimmel Comprehensive Cancer Center. Dr. Pardoll completed his MD, PhD, Medical Residency and Oncology Fellowship at Johns Hopkins University. Dr. Pardoll has published over 200 papers as well as over 20 book chapters on the subject of T cell immunology and cancer vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell, and has served as a member of scientific advisory boards for the Cancer Research Institute, the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard-Dana Farber Cancer Center, Aduro Biotech, Cerus Corporation, Global Medical Products Corporation, Genencor Corporation, Cell Genesys Corporation, Mojave Therapeutics, the American Association of Clinical Oncology and the American Association of Cancer Research. Dr. Pardoll has made a number of basic advances in cellular immunology, including the discovery of gamma-delta T cells, NKT cells and interferon-producing killer dendritic cells. Over the past two decades, Dr. Pardoll has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes-based cancer vaccines.
Dan Watkins, PhD
Partner, Mercury Fund
Dan Watkins co-founded Mercury Fund where he leads the Sciences team. He focuses on both Physical and Life Science startups, many at the formation or university spinoff stage. Dr. Watkins has served in a number of operational roles including initial CEO of DNAtrix and Nanospectra Biosciences, both oncology companies. Prior to Mercury, he has been Vice President at a boutique investment banking firm and Worldwide Manager of Operations Control Systems for Scientific Software Intercomp. Dr. Watkins serves on the board of directors of a number of life sciences companies including: DNAtrix, GlycosBio (industrial biotechnology), Swift Biosciences (next generation sequencing), Sinopsys (medical device) and Resonant (novel antibody discovery). Dr. Watkins received his BS from Rice University and his MS and PhD from Carnegie Mellon University, all in Materials Science. Dan serves on the advisory boards of Northwestern University’s Innovation and New Ventures Office (INVO), the University of Michigan’s Venture Center Council, and BioHouston. He is also the co-founder of the Rice Alliance for Technology and Entrepreneurship at Rice University.